BIOMAD
ActiveFinancials · financial year 2025, micro format
2025 annual accounts filed 56 days after the deadline Filed on 25 September 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00524286.
Annual accounts 2025 filed on 25-09-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2025 is a loss of €2,256, smaller than the loss of €5,477 in 2024.
Turnover and EBIT margin are not published. The micro format does not require them.
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Other operating charges640/8 | €1,500 | - | - |
| Gross operating margin9900 | -€3,977 | -€2,256 | ▲ 43.3% |
| Operating profit (loss)9901 | -€5,477 | -€2,256 | ▲ 58.8% |
| Financial charges65/66B | €64 | €150 | ▲ 134% |
| Recurring financial charges65 | €64 | €150 | ▲ 134% |
| Profit (loss) for the period before taxes9903 | -€5,541 | -€2,406 | ▲ 56.6% |
| Profit (loss) for the period9904 | -€5,541 | -€2,406 | ▲ 56.6% |
| Profit (loss) for the period to be appropriated9905 | -€5,541 | -€2,406 | ▲ 56.6% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €15,604 | €13,459 | ▼ 13.7% |
| Current assets29/58 | €15,604 | €13,459 | ▼ 13.7% |
| Cash at bank and in hand54/58 | €15,604 | €13,459 | ▼ 13.7% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €15,604 | €13,459 | ▼ 13.7% |
| Equity10/15 | €12,459 | €10,053 | ▼ 19.3% |
| Contributions10/11 | €18,000 | €18,000 | = |
| Profit (loss) carried forward14 | -€5,541 | -€7,947 | ▼ 43.4% |
| Amounts payable17/49 | €3,145 | €3,406 | ▲ 8.3% |
| Amounts payable within one year42/48 | €3,145 | €3,406 | ▲ 8.3% |
| Other amounts payable47/48 | €3,145 | €3,406 | ▲ 8.3% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€5,541 | -€2,406 | ▲ 56.6% |
| Operating cash flow (approximation) | -€5,541 | -€2,406 | ▲ 56.6% |
| Change in cash | - | -€2,145 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 3,223 companies had the same profile as BIOMAD has now. Two years later, 87.8% were still going and 3.4% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of BIOMAD itself: 0.9% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,223 companies, not a prediction for BIOMAD. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.